Watch OSTX. Know when insiders buy.
One email the day a filing lands. Free.
OSTX
OS Therapies Inc
1.66
+0.01 +0.61%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · shorts 34
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $76.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$39.4MNET CASH —52W 1.16 – 2.24SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$8.6M | −$8.6M | — | -0.20 | −$5.5M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$10.2M | −$10.4M | — | -0.27 | −$4.6M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$12M | −$13.5M | — | -0.41 | −$3.7M | $0 | −$3.7M | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$6.9M | −$6.9M | — | -0.21 | −$4.7M | $0 | −$4.7M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.8M | −$4.5M | — | -0.19 | −$2.4M | $316K | −$2.7M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$5M | −$3.9M | — | -0.18 | −$3.4M | $150K | −$3.6M | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3M | −$3M | — | -0.64 | −$2.4M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$2.4M | −$2.9M | — | -0.18 | −$3.4M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$780K | −$1.6M | — | -0.26 | −$881K | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$630K | −$1.5M | — | -0.25 | −$642K | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.2M | −$1.5M | — | -0.85 | −$871K | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$622K | −$2M | — | -0.38 | −$877K | $0 | −$877K | Nov 15 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$28.7M | −$28.8M | — | -0.98 | −$14.2M | $466K | −$14.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$6.8M | −$8.9M | — | -1.28 | −$7.3M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$4.3M | −$7.8M | — | -1.46 | −$3M | — | — | — | — |
Every number comes from OS Therapies Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.